세계 안정 동위체 표지 화합물 시장 : 유형별, 용도별, 최종 사용자별 - 기회 분석과 산업 예측(2024-2035년)

Stable Isotope Labeled Compounds Market By Type, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2024-2035

US $ 4,425 ￦ 6,062,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 7,412 ￦ 10,155,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

안정 동위체 표지 화합물 시장은 2023년에는 2억 9,182만 달러가 되고, 2024년부터 2035년까지의 CAGR은 3.1%를 예상하며, 2035년까지는 4억 2,010만 달러에 이를 것으로 예측됩니다.

안정 동위체 표지 화합물은 하나 이상의 원자가 탄소 13(^13C), 질소 15(^15N), 중수소(^2H)와 같은 비방사성 동위원소로 대체된 분자입니다. 이러한 동위 원소는 화학적으로 자연적으로 발생하는 것과 동일하지만 원자 질량이 다르기 때문에 방사선을 방출하지 않고 추적 할 수 있습니다. 연구 및 산업 응용 분야에서 널리 사용되며 대사 경로, 의약품 개발 및 환경 프로세스 연구에 중요한 역할을 합니다. 비방사성이기 때문에 생물학적 분석이나 화학적 분석에 안전하게 사용할 수 있으며 분자 거동, 반응 메커니즘 및 상호작용에 대한 상세한 수준에서 귀중한 지식을 얻을 수 있습니다.

안정 동위체 표지 화합물시장의 성장은 다양한 분야에서 유용성을 높이는 다양한 상호 관련 요소에 크게 영향을 받고 있습니다. 질량분석과 핵자기공명(NMR)과 같은 고급 분석 기술에 대한 수요 증가는 매우 중요한 역할을 합니다. 이러한 기술은 정확한 측정과 고해상도 분석을 달성하기 위해 안정 동위체 표지 화합물에 크게 의존하므로 성장을 더욱 촉진하고 있습니다. 연구 및 진단 용도가 고도화됨에 따라 정확하고 신뢰할 수 있는 분석 도구에 대한 필요성이 커지고 시장 성장을 더욱 강화하고 있습니다. 또한, 환경 연구에서 안정 동위체 표지 화합물의 용도 증가는 범용성을 돋보이게합니다. 이러한 화합물은 오염물질 추적 및 환경 변화 모니터링에 사용되며 규제 및 환경 보전 노력에 필수적인 데이터를 제공합니다. 이러한 응용은 세계 환경 과제에 대응하는 안정 동위체 표지 화합물의 중요성을 높여 시장 성장을 가속합니다.

임상시험과 단백질체학 연구의 확대는 또 다른 중요한 추진력이 되고 있습니다. 안정 동위체 표지 화합물은 약물 대사와 생체계의 복잡한 상호 작용을 이해하는 데 필수적입니다. 임상시험은 신약의 대사 경로를 추적하는 데 도움이 되며, 단백질체학는 단백질의 정확한 정량 및 추적을 가능하게 합니다. 임상 및 단백질체학의 응용 분야에서 이러한 성장은 의학 연구와 맞춤형 의료를 전진시키기 위해 이러한 화합물에 대한 의존성이 증가하고 있음을 반영합니다.

게다가 연구자와 임상의 사이에서 안정 동위체 표지 화합물에 대한 인식과 채용이 높아지고 있는 것도 시장 성장을 가속하는 주요 요인이 되고 있습니다. 연구자와 임상의는 다양한 연구의 정확성과 신뢰성을 높이는 능력과 같은 안정동위체 표지화합물과 관련된 이점에 익숙해짐에 따라 이러한 화합물의 사용량이 증가하고 있습니다. 이러한 안정동위체 표지화합물의 가치에 대한 인식 증가는 다양한 과학·임상분야에서 수요 증가에 더욱 기여하여 시장 전체의 성장을 가속하는 시너지 효과를 창출하고 있습니다.

안정동위체 표지화합물 시장은 유형, 용도, 최종 사용자, 지역으로 구분됩니다. 유형별로 시장은 중수소, 탄소-13, 산소-18, 질소-15 등으로 구분됩니다. 용도별로 시장은 연구, 임상 진단 등으로 분류됩니다. 연구 부문은 생물 의학 연구, 제약 연구 등으로 나뉩니다. 최종 사용자별로는 제약·바이오테크놀러지 기업, 학술기관 및 연구기관, 병원 및 진단센터, 기타 최종 사용자로 분류됩니다. 지역별로 시장은 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카에서 분석됩니다.

이해관계자를 위한 주요 이점

• 본 보고서에서는 2023년부터 2035년까지의 안정 동위체 표지 화합물 시장 분석 시장 부문, 현재의 동향, 추정·동향, 역학을 정량적으로 분석하여 유력한 안정 동위체 표지 화합물 시장 기회를 특정합니다.
• 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• 포터의 Five Force Analysis는 이해관계자가 이익에 중점을 둔 비즈니스 결정을 내리고 공급업체와 구매자의 네트워크를 강화할 수 있도록 구매자와 공급업체의 잠재력을 강조합니다.
• 안정동위체 표지화합물 시장의 세분화를 상세하게 분석함으로써 시장 기회를 파악할 수 있습니다.
• 각 지역의 주요 국가는 세계 시장에 대한 수익 공헌도에 따라 매핑됩니다.
• 시장 기업 포지셔닝은 벤치마킹을 용이하게 하고 시장 기업의 현재 위치를 명확하게 이해할 수 있습니다.
• 지역별 및 세계 안정 동위체 표지 화합물 시장 동향, 주요 기업, 시장 부문, 응용 분야, 시장 성장 전략 등의 분석을 포함합니다.

이 보고서에서 가능한 보고서 사용자 정의(추가 비용 및 일정이 있습니다.)

• 국가, 지역, 세계 수준의 환자 역학 데이터
• 규제 가이드라인
• 고객의 관심에 따른 추가 기업 프로파일
• 국가별 또는 지역별 추가 분석 - 시장 규모 및 예측
• 기업 프로파일의 확장 목록
• 과거 시장 데이터
• SWOT 분석

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장 정의와 범위
• 주요 조사 결과
  • 주요 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
    • 암 이환율의 상승과 조사의 진보
    • 정부의 자금 지원 및 지원 확대
    • 주요 기업에 의한 전략 채용 증가
  • 억제요인
    • 제조 비용의 높이와 기술적 복잡성
  • 기회
    • 신흥국의 성장 기회

제4장 안정 동위체 표지 화합물 시장 : 유형별

• 개요
• 중수소
• 탄소 13
• 산소 18
• 질소 15
• 기타

제5장 안정 동위체 표지 화합물 시장 : 용도별

• 개요
• 연구
  • 연구용 안정 동위체 표지 화합물 시장 : 유형별
• 임상 진단
• 기타

제6장 안정 동위체 표지 화합물 시장 : 최종 사용자별

• 개요
• 제약기업 및 바이오테크놀러지기업
• 학술기관 및 연구기관
• 병원 및 진단센터
• 기타

제7장 안정 동위체 표지 화합물 시장 :지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 기타
• 라틴아메리카, 중동 및 아프리카
  • 브라질
  • 남아프리카
  • 사우디아라비아
  • 기타

제8장 경쟁 구도

• 소개
• 주요 성공 전략
• 주요 10개사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2023년

제9장 기업 프로파일

• Merck KGaA
• Otsuka Holdings Co., Ltd.
• Entegris
• Omicron Biochemicals, Inc.
• Shimadzu Corporation
• Silantes
• VIVAN Life Sciences
• BOC Sciences
• Symeres
• NIPPON SANSO HOLDINGS CORPORATION

SHW

영문 목차

영문목차

The stable isotope labeled compounds market was valued at $291.82 million in 2023 and is estimated to reach $420.1 million by 2035, exhibiting a CAGR of 3.1% from 2024 to 2035. Stable isotope-labeled compounds are molecules where one or more atoms are replaced with non-radioactive isotopes, such as carbon-13 (^13C), nitrogen-15 (^15N), deuterium (^2H), and others. These isotopes are chemically identical to their naturally occurring counterparts but differ in atomic mass, allowing them to be tracked without emitting radiation. Widely used in research and industrial applications, they play a crucial role in studying metabolic pathways, drug development, and environmental processes. Their non-radioactive nature makes them safe for use in both biological and chemical analyses, providing valuable insights into molecular behavior, reaction mechanisms, and interactions at a detailed level.

The growth of the stable isotope-labeled compounds market is significantly influenced by a range of interconnected factors that enhance its utility across various fields. The rise in demand for advanced analytical techniques such as mass spectrometry and nuclear magnetic resonance (NMR) plays a pivotal role. These techniques rely majorly on stable isotope-labeled compounds to achieve precise measurements and high-resolution analysis, thus driving their adoption. The need for accurate and reliable analytical tools increases, as research and diagnostic applications become sophisticated, further fueling market growth. In addition, the increase in application of stable isotope-labeled compounds in environmental studies highlights their versatility. These compounds are used to trace pollutants and monitor environmental changes, providing crucial data for regulatory and conservation efforts. This application drives the growing importance of stable isotope-labeled compounds in addressing global environmental challenges, thus fostering the market growth.

The expansion of clinical trials and proteomics studies represents another crucial driver. Stable isotope-labeled compounds are essential for understanding drug metabolism and the complex interactions within biological systems. In clinical trials, they help in tracing the metabolic pathways of new drugs, while in proteomics, they enable precise protein quantification and tracking. This growth in clinical and proteomics applications reflects the increasing reliance on these compounds for advancing medical research and personalized medicine.

Moreover, the rise in awareness and adoption of stable isotope-labeled compounds among researchers and clinicians is a key factor driving the market growth. There is an increase in the usage of these compounds as researchers and clinicians become familiar with the benefits associated with them, including their ability to enhance accuracy and reliability in various studies. This growing recognition of the value of stable isotope-labeled compounds further contributes to their increasing demand across diverse scientific and clinical fields, creating a synergistic effect that drives the overall market growth.

The stable isotope-labeled compounds market is segmented into type, application, end user, and region. On the basis of type, the market is segmented into Deuterium, Carbon-13, Oxygen-18, Nitrogen-15, and others. On the basis of application, the market is classified into research, clinical diagnostics, and other. The research segment is further divided into biomedical research, pharma research, and others. On the basis of end user, the market is categorized into pharmaceutical and biotechnology companies, academic and research institutes, hospitals and diagnostic centers, and other end users. On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include Merck KGaA, Otsuka Holdings Co., Ltd., Entegris, Omicron Biochemicals, Inc., Shimadzu Corporation, Nippon Sanso Holding Corporation, Vivan Life Sciences, BOC Sciences, Silantes, and Symeres. The key players have adopted product launch, geographical expansion, partnership, and agreement as the key strategies to expand their product portfolio.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the stable isotope labeled compounds market analysis from 2023 to 2035 to identify the prevailing stable isotope labeled compounds market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the stable isotope labeled compounds market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global stable isotope labeled compounds market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Patient/epidemiology data at country, region, global level
• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• SWOT Analysis

Key Market Segments

By Type

• Deuterium
• Carbon 13
• Oxygen 18
• Nitrogen15
• Other

By Application

• Research
  • Type
  • Biomedical Research
  • Pharma Research
  • Others
• Clinical Diagnostics
• Others

By End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Hospitals and Diagnostic Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • South Africa,
  • Saudi Arabia
  • Rest of LAMEA

Key Market Players:

• BOC Sciences
• Entegris
• Merck KGaA
• NIPPON SANSO HOLDINGS CORPORATION
• Omicron Biochemicals, Inc.
• Otsuka Holdings Co., Ltd.
• Shimadzu Corporation
• Silantes
• Symeres
• VIVAN Life Sciences

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Moderate bargaining power of suppliers
  • 3.3.2. Moderate threat of new entrants
  • 3.3.3. Moderate threat of substitutes
  • 3.3.4. Moderate intensity of rivalry
  • 3.3.5. Moderate bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Rise in Cancer Prevalence and Advancements in Research
    • 3.4.1.2. Growing Government Funding and Support
    • 3.4.1.3. Rise in adoption of strategies by the key players
  • 3.4.2. Restraints
    • 3.4.2.1. High Production Costs and Technical Complexity
  • 3.4.3. Opportunities
    • 3.4.3.1. Growth Opportunity in emerging countries

CHAPTER 4: STABLE ISOTOPE LABELED COMPOUNDS MARKET, BY TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Deuterium
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Carbon 13
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Oxygen 18
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Nitrogen15
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country
• 4.6. Other
  • 4.6.1. Key market trends, growth factors and opportunities
  • 4.6.2. Market size and forecast, by region
  • 4.6.3. Market share analysis by country

CHAPTER 5: STABLE ISOTOPE LABELED COMPOUNDS MARKET, BY APPLICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Research
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
  • 5.2.4. Research Stable Isotope Labeled Compounds Market by Type
• 5.3. Clinical Diagnostics
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Others
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country

CHAPTER 6: STABLE ISOTOPE LABELED COMPOUNDS MARKET, BY END USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Pharmaceutical and Biotechnology Companies
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Academic and Research Institutes
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Hospitals and Diagnostic Centers
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country
• 6.5. Others
  • 6.5.1. Key market trends, growth factors and opportunities
  • 6.5.2. Market size and forecast, by region
  • 6.5.3. Market share analysis by country

CHAPTER 7: STABLE ISOTOPE LABELED COMPOUNDS MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Type
  • 7.2.3. Market size and forecast, by Application
  • 7.2.4. Market size and forecast, by End User
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Type
    • 7.2.5.1.2. Market size and forecast, by Application
    • 7.2.5.1.3. Market size and forecast, by End User
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Type
    • 7.2.5.2.2. Market size and forecast, by Application
    • 7.2.5.2.3. Market size and forecast, by End User
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Type
    • 7.2.5.3.2. Market size and forecast, by Application
    • 7.2.5.3.3. Market size and forecast, by End User
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Type
  • 7.3.3. Market size and forecast, by Application
  • 7.3.4. Market size and forecast, by End User
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Type
    • 7.3.5.1.2. Market size and forecast, by Application
    • 7.3.5.1.3. Market size and forecast, by End User
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Type
    • 7.3.5.2.2. Market size and forecast, by Application
    • 7.3.5.2.3. Market size and forecast, by End User
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Type
    • 7.3.5.3.2. Market size and forecast, by Application
    • 7.3.5.3.3. Market size and forecast, by End User
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Type
    • 7.3.5.4.2. Market size and forecast, by Application
    • 7.3.5.4.3. Market size and forecast, by End User
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Type
    • 7.3.5.5.2. Market size and forecast, by Application
    • 7.3.5.5.3. Market size and forecast, by End User
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Type
    • 7.3.5.6.2. Market size and forecast, by Application
    • 7.3.5.6.3. Market size and forecast, by End User
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Type
  • 7.4.3. Market size and forecast, by Application
  • 7.4.4. Market size and forecast, by End User
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Type
    • 7.4.5.1.2. Market size and forecast, by Application
    • 7.4.5.1.3. Market size and forecast, by End User
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Type
    • 7.4.5.2.2. Market size and forecast, by Application
    • 7.4.5.2.3. Market size and forecast, by End User
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Type
    • 7.4.5.3.2. Market size and forecast, by Application
    • 7.4.5.3.3. Market size and forecast, by End User
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Type
    • 7.4.5.4.2. Market size and forecast, by Application
    • 7.4.5.4.3. Market size and forecast, by End User
    • 7.4.5.5. Rest of Asia-Pacific
    • 7.4.5.5.1. Market size and forecast, by Type
    • 7.4.5.5.2. Market size and forecast, by Application
    • 7.4.5.5.3. Market size and forecast, by End User
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Type
  • 7.5.3. Market size and forecast, by Application
  • 7.5.4. Market size and forecast, by End User
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Type
    • 7.5.5.1.2. Market size and forecast, by Application
    • 7.5.5.1.3. Market size and forecast, by End User
    • 7.5.5.2. South Africa,
    • 7.5.5.2.1. Market size and forecast, by Type
    • 7.5.5.2.2. Market size and forecast, by Application
    • 7.5.5.2.3. Market size and forecast, by End User
    • 7.5.5.3. Saudi Arabia
    • 7.5.5.3.1. Market size and forecast, by Type
    • 7.5.5.3.2. Market size and forecast, by Application
    • 7.5.5.3.3. Market size and forecast, by End User
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Market size and forecast, by Type
    • 7.5.5.4.2. Market size and forecast, by Application
    • 7.5.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2023

CHAPTER 9: COMPANY PROFILES

• 9.1. Merck KGaA
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Otsuka Holdings Co., Ltd.
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. Entegris
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
• 9.4. Omicron Biochemicals, Inc.
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
• 9.5. Shimadzu Corporation
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
• 9.6. Silantes
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
• 9.7. VIVAN Life Sciences
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
• 9.8. BOC Sciences
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
• 9.9. Symeres
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
• 9.10. NIPPON SANSO HOLDINGS CORPORATION
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance

관련자료